tetano
Editor, Senior Moderator
Can Respir J. 2019 Apr 30;2019:3859230. doi: 10.1155/2019/3859230. eCollection 2019.
[h=1]A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia.[/h] Wang JN[SUP]1[/SUP], Wang X[SUP]1[/SUP], Yu SL[SUP]1[/SUP], Ding YH[SUP]1[/SUP], Wang ML[SUP]1[/SUP], Chen HD[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Objective:[/h] To evaluate the difference of clinical efficacy of peramivir alone and peramivir combined with immunomodulators (either ribonucleic acid or thymopetidum) in the treatment of severe influenza A with primary viral pneumonia.
[h=4]Methods:[/h] A retrospective analysis was applied to 45 patients who were diagnosed with severe influenza A with primary viral pneumonia in our hospital from December 2017 to March 2018. The cases were divided into three groups: the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group.
[h=4]Results:[/h] The duration of viral nucleic acid positivity in the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 6.13 ? 2.06, 6.53 ? 2.72, and 6.10 ? 1.37 days, respectively. The remission time of the clinical symptoms of the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 8.06 ? 2.73, 7.94 ? 2.89, and 7.67 ? 1.58 days, respectively. Comparisons between the peramivir group and the peramivir combined with ribonucleic acid group or the peramivir combined with thymopetidum group revealed no significant differences in the duration of virus nucleic acid positivity, remission time of clinical symptoms, time to fever alleviation, and time to cough alleviation.
[h=4]Conclusions:[/h] There is no observed benefit in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia. This trial is registered with ChiCTR1800019417.
PMID: 31182983 PMCID: PMC6515146 DOI: 10.1155/2019/3859230
Free PMC Article
[h=1]A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia.[/h] Wang JN[SUP]1[/SUP], Wang X[SUP]1[/SUP], Yu SL[SUP]1[/SUP], Ding YH[SUP]1[/SUP], Wang ML[SUP]1[/SUP], Chen HD[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Objective:[/h] To evaluate the difference of clinical efficacy of peramivir alone and peramivir combined with immunomodulators (either ribonucleic acid or thymopetidum) in the treatment of severe influenza A with primary viral pneumonia.
[h=4]Methods:[/h] A retrospective analysis was applied to 45 patients who were diagnosed with severe influenza A with primary viral pneumonia in our hospital from December 2017 to March 2018. The cases were divided into three groups: the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group.
[h=4]Results:[/h] The duration of viral nucleic acid positivity in the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 6.13 ? 2.06, 6.53 ? 2.72, and 6.10 ? 1.37 days, respectively. The remission time of the clinical symptoms of the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 8.06 ? 2.73, 7.94 ? 2.89, and 7.67 ? 1.58 days, respectively. Comparisons between the peramivir group and the peramivir combined with ribonucleic acid group or the peramivir combined with thymopetidum group revealed no significant differences in the duration of virus nucleic acid positivity, remission time of clinical symptoms, time to fever alleviation, and time to cough alleviation.
[h=4]Conclusions:[/h] There is no observed benefit in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia. This trial is registered with ChiCTR1800019417.
PMID: 31182983 PMCID: PMC6515146 DOI: 10.1155/2019/3859230
Free PMC Article